The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 13, 2025

Filed:

Dec. 19, 2019
Applicants:

Sichuan Kelun-biotech Biopharmaceutical Co., Ltd., Sichuan, CN;

Klus Pharma Inc., Cranbury, NJ (US);

Inventors:

Haijun Tian, Cranbury, NJ (US);

Sujun Deng, Cranbury, NJ (US);

Chunxia Zhao, Cranbury, NJ (US);

Hong Li, Cranbury, NJ (US);

Dengnian Liu, Sichuan, CN;

Hu Long, Sichuan, CN;

Cheng Wang, Sichuan, CN;

Liang Xiao, Sichuan, CN;

Tongtong Xue, Sichuan, CN;

Jingyi Wang, Sichuan, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/337 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 31/337 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/464 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding the antibody and fragment, and method for preparing the antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Also provided herein is a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs for the prevention and/or treatment of tumors.


Find Patent Forward Citations

Loading…